Summit Therapeutics Refocuses on Oncology Drug After Antibiotic Sale

1. Cori Fisher wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
2. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
3. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Summit Therapeutics Inc. (SMMT:NASDAQ; SUMM:LON) is revamping its space in the pharma sector, pivoting from antibiotics to cancer care in hopes of answering a growing market demand. 

Key Takeaways

• Summit Therapeutics sold ridinilazole, an investigational Phase III precision antibiotic for C. difficile infection, to Toronto-based Biossil.
• Ridinilazole's Phase III Ri-CoDIFy study showed a higher Sustained Clinical Response rate than vancomycin but did not meet the primary endpoint for superiority.
• Biossil, an AI-native biopharma company with teams in Toronto and Boston, plans to continue clinical development of ridinilazole, with CSO Alexander Mosa citing the need for new approaches to recurrent C. difficile and antibiotic resistance.
• Summit will focus on its core oncology drug, ivonescimab, moving forward.

Summit Sells Ridinilazole Rights to AI-Native Biopharma Biossil

On July 16, 2026, U.S.-based biopharma company Summit Therapeutics announced an agreement to sell its investigational Phase 3 antibiotic, ridinilazole, to Biossil, Inc. — an AI-native biopharma company focused on advancing late-stage programs in life-threatening indications with urgent medical needs. The terms of the agreement state that Summit will receive US$500,000 in up-front payment, with up to US$104.5 million in regulatory and commercial milestones, as well as tiered royalties on net sales. The drug has not yet been evaluated or approved by the U.S. Food and Drug Administration (FDA).

"Introduction of novel, microbiome-sparing antibiotics has lagged the growing global need," said Alexander Mosa, MD, Ph.D., CSO, and Chair of Biossil. "Recurrent C. difficile infection, selection of antibiotic-resistant genes, and gut dysbiosis are common, burdensome, and in need of new approaches. We thank Summit for entrusting us with continued development of ridinilazole, and we will advance this program with urgency and focus."

C. difficile, commonly known as C. diff or CDI, is a bacterial infection of the colon causing inflammation, severe watery diarrhea, painful abdominal cramping, nausea, fever, and dehydration. In more severe cases, the infection can even lead to bowel perforation, sepsis, and death. Unfortunately, this disease is communicable and highly contagious, and the Peggy Lillis Foundation claims that ". . . C. difficile causes nearly 500,000 infections in the United States each year and contributes to more than 29,000 deaths annually." In 2024, the Centers for Disease Control (CDC) cataloged 124.4 cases per 100,000 people, with most cases due to recent antibiotic exposure or overexposure. The eventual goal of Ridinilazole is to provide the market with an antibiotic that will have a lower association with the infection.

Moving forward, Summit Therapeutics will focus on its investigational oncology drug, ivonescimab, for treating patients with EGFR-mutant locally advanced or metastatic non-small cell lung cancer who have progressed on or following growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) treatment.

Summit Therapeutics is a biopharma company with the mission of building ". . .  viable, long-lasting health care organization that assumes full responsibility for designing, developing, trial execution and enrollment, regulatory submission and approval, as well as successful commercialization of patient-, physician-, caregiver-, and societal-friendly medicinal therapy intended to: improve quality of life, increase potential duration of life, and resolve serious medical healthcare needs." 

Cancer Cases Rise as Treatment Costs Skyrocket

In February 2026, Iqvia discussed the global pharma market projection for 2026, noting that total drug usage is expected to surpass four trillion doses daily by 2030. They wrote, "The largest drivers of medicine spending growth through the next five years will continue to be the use in developed markets of innovative therapeutics, especially in oncology, immunology, diabetes, and obesity."

Pharma sector funding fell between 2024 and 2025, according to a March 26, 2026, article for Fierce Biotech by Nick Paul Taylor.  He wrote that pharma funding had fallen from 2024 but noted that, "2025 was still the third-best year of the past decade. Similarly, overall funding was well above the pre-pandemic norm and only topped by 2020, 2021, and 2024."

The global cancer treatment sector, unfortunately, shows no signs of shrinking. A March 26, 2026, article by Kinjel Shah for Yahoo Finance claimed that cancer incidences were rising. He quoted the American Cancer Society as expecting 2.1 million new cancer cases and over 626,000 cancer-related deaths in 2026. However, technology is ever-evolving to keep up with the disease.

Shah wrote, "Emerging technologies such as genomic sequencing, artificial intelligence, and machine learning are accelerating biomarker discovery, enhancing patient stratification, and enabling earlier and more accurate diagnoses. While a universal cure remains out of reach, consistent improvements in survival rates and patient outcomes across multiple cancer types highlight the tangible benefits of these advances, particularly when combined with earlier detection and intervention."

This innovation comes at a price. In February 2026, Keith Speights wrote an article for The Motley Fool discussing rising care costs, stating that cancer treatments in the U.S. cost roughly US$200 billion in 2020 but are expected to increase to more than US$245 billion by 2030.

BCG talked about trends biopharma companies need to be aware of in 2026 in order to stay competitive, saying, "Near term, companies need to continue to innovate to decrease the complexity and cost of these therapies, and governments can find ways to incentivize and pay for them. The longer-term challenge for companies is to factor operational and economic considerations into R&D decision making earlier, ensuring that trial designs match real-world usage, indication sequences match opportunity, and endpoints enable market access."

Harmoni-3 Global Data Seen as Key Turning Point

Bill Maughan, Ph.D., of Clear Street gave Summit Therapeutics a "Buy" rating on April 30, 2026, with a price target of US$31.00. Maughan noted that the company's Q1 2026 results were presumed negative since the interim Pre-Feasibility Study for its Harmoni-3 trial were withheld from the public. In defense of Summit Therapeutics, Maughan wrote: " While we agree that the update is negative, we see it as incremental, as the statistical bar for success was high. Further, HARMONi-6 PFS data in a similar population (Chinese only vs. global) were clearly positive, and translation from a Chinese population to global, while often showing some regression, is still well correlated. We think strong data from HARMONi-6 at ASCO should help calm concerns regarding the HARMONi-3 trial. We expect the result to be positive and show a statistically significant OS benefit."

A July 16, 2026, analyst rating, however, gave the company a "Neutral" rating, declining to provide a price target at all. Mitchell Kapoor of H.C. Wainwright & Co. wrote: "HARMONi-3 must establish global relevance. HARMONi-6 demonstrated that ivonescimab + chemotherapy can produce a survival benefit in 1L squamous (SQ) NSCLC, but its China-only design and tislelizumab comparator do not establish that the benefit reproduces against KEYTRUDA-based standard of care across multiple regions. Lung06 carries the same China-to-global limitation and currently lacks quantified efficacy and survival data, but it has a more relevant population and control for the HARMONi-3 NSQ cohort. A clear HARMONi-3 win would carry greater global regulatory and commercial relevance than either China-only study and could restore ivo's leadership, but OS is a gating item for the stock. The pressure on SMMT is that HARMONi-3 must now deliver against a control regimen sac-TMT has already beaten in the same subpopulation, after Lung05 had placed sac-TMT ahead across much of the broader 1L market."

Harmoni-3 Interim Data and BLA Filing Expected in H2 2026

According to the company's investor presentation, ivonescimab is currently undergoing or planned to undergo several trials, including:

• Harmoni: enrollment complete
• Harmoni-3: SQ enrollment complete; nSQ screening complete
• Harmoni-7: enrolling
• Harmoni-G13: enrolling

In the second half of 2026, Summit Therapeutics plans to release a Pre-Feasibility complete and interim OS data from the Harmoni-3 SQ study and provide a BLA date in November. In the first half of 2027, the company anticipates the Pre-Feasibility Study readout.

Ownership & Share Information¹

Summit Therapeutics Inc. has a market cap of US$11.70 billion, with 776.16 million shares outstanding. The company's 52-week range is US$12.55-US$30.98. Institutions own 15.84% of shares, while Management & Insiders own 83.14%. The remaining 1.02% of shares are Retail.

Frequently Asked Questions

Q: What is an investigational drug?

A: An investigational drug is a medicine that is still being studied and has not yet been approved for sale by regulators such as the U.S. Food and Drug Administration (FDA). It must go through clinical trials to show that it is safe and effective before it can become an approved treatment.

Q: What is a BLA, and why does it matter?

A: A Biologics License Application (BLA) is the formal request a company submits to the U.S. Food and Drug Administration (FDA) to seek approval for a biological medicine. If Summit files its BLA as planned, it would mark an important step toward potentially bringing ivonescimab to patients, pending FDA review.

Q: What is a Phase 3 clinical trial?

A: A Phase 3 clinical trial is one of the final stages of testing before a company asks regulators to approve a new medicine. It typically compares a new treatment with the current standard of care in a large group of patients to determine whether it is safe and effective.

Q: Why do investors pay attention to drugs that are still in clinical trials?

A: For biotech companies, medicines in development are often their most valuable assets. Positive clinical trial results can move a drug closer to regulatory approval and future sales, while unsuccessful trials can delay or end a program. As a result, investors closely watch trial milestones because they can have a major impact on a company's future.